GPP
OKUR

Great Point Partners’s OnKure Therapeutics OKUR Stock Holding History

Great Point Partners’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-116,706
Closed -$8.89M – 47
2023
Q3 		$8.89M Buy
116,706
+8,374
+8% +$570K 1.62% 28
2023
Q2 		$7.11M Buy
108,332
+96,246
+796% +$7.75M 1.39% 25
2023
Q1 		$723K Buy
+12,086
New +$438K 0.14% 43

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Great Point Partners's OKUR Position: Q4 2023 in Review

Great Point Partners sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 116,706 shares — an estimated $8.89M sold.

Great Point Partners first reported a position in OKUR in Q1 2023 and held it in 3 quarters. The position peaked at $8.89M in Q3 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

  • Great Point Partners reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 116,706 OnKure Therapeutics shares in Q4 2023, an estimated $8.89M.
  • Great Point Partners first reported a position in OnKure Therapeutics in Q1 2023 and held it in 3 quarters.
  • Great Point Partners's OnKure Therapeutics position peaked at $8.89M in Q3 2023.
  • 68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.